TreatSMA joins hands with Genetic Alliance to improve the situation of people with SMA

Improving the UK scene in rare and genetic diseases is no minor task. For example, our country holds the sad record of having the lowest availability of orphan drugs in Western Europe.*

Genetic Alliance works to change this. They try to address many issues: reproductive techniques, diagnosis, medical research, healthcare and delivery, access to treatments, and living and education. You can read about their work here.

They also run the National Campaign for Rare Diseases.

On Rare Disease Day, TreatSMA was approved as a member of Genetic Alliance.

We will now work together to change the country for better for all people with SMA.

* See for instance this report

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more